Compounded and brand: what differs

Three different things, one word

People say semaglutide or tirzepatide as though the word settled what is in the syringe. It does not, and Mira spends a good part of the compounded-to-brand-switch circle untangling this before anything else can be discussed sensibly.

There are three categories. A licensed product is a specific formulation from a specific manufacturer that a regulator has authorised for a specific indication, dispensed in the device it was authorised in. A compounded preparation is made by a pharmacy for a patient, under rules that vary considerably between countries, and is not an authorised product — it exists in a regulatory space designed for preparing things that are not commercially available. Research-use-only material is not a medicine at all in any sense; it was never manufactured, released or documented as one, and we have a whole guide about that.

These are not points on a quality spectrum from best to worst. They are three different legal and manufacturing contexts, with different things guaranteed in each and different things left open.

What a marketing authorisation actually buys

When a regulator authorises a product, a set of specific machinery attaches to it, and it is worth naming the parts because otherwise brand versus compounded sounds like a question of price and packaging.

You get an assessed dossier: the quality, safety and efficacy data were reviewed by people whose job is to find the holes. You get manufacture under good manufacturing practice at inspected sites, which is the mechanism that controls sterility and cross-contamination. You get batch release by a responsible person before any of it reaches a patient. You get stability data, which is where in-use and storage instructions come from rather than from custom. You get a leaflet whose wording was approved. You get pharmacovigilance — a system that collects reports of harm and can detect a signal across a population. You get a recall mechanism that can pull a batch back through the supply chain. And you get somebody legally accountable if it goes wrong.

Mira’s framing: none of that makes a licensed product right for you, and plenty of people cannot get one. It does mean the failure modes are different, and knowing which set you are exposed to is the point of understanding the distinction at all.

Compounding is not one thing

Members talk across each other constantly here, because compounded means something different in each of their countries.

In the United States, compounding runs under two statutory routes: pharmacies compounding for an identified patient, and outsourcing facilities that register with the federal regulator and work to stricter manufacturing standards. Compounding of a copy of a commercially available drug is restricted, and the shortage listings that permitted widespread compounding of these molecules changed as shortages were declared resolved — the position has moved more than once and continues to.

In the United Kingdom, unlicensed medicines are supplied as specials under a narrow framework intended for cases where no licensed product meets a patient’s need, and specials manufacture is itself licensed and inspected. Compounding a copy of an available licensed product is not what that framework is for.

Across the European Union, magistral and officinal preparation exists in national law with real variation between member states. In Australia, the regulator has restricted compounding of these molecules substantially. In Canada, compounding sits with provincial pharmacy regulators rather than with the federal one.

The practical upshot: "compounded is legal where my friend lives" tells you nothing about where you live, and the conditions attached usually matter more than the permission does.

Salt forms and the sequence question

A technical point that turned into a public one. Regulators in more than one country have warned about preparations using salt forms — semaglutide sodium and semaglutide acetate — which are different substances from the base form in the authorised products. A salt form has not been shown to be equivalent in safety or effectiveness, and its use was one of the regulatory flashpoints of the compounding era.

The related concern is sequence and modification. These molecules are not simple: semaglutide carries a fatty-acid side chain and specific amino acid substitutions that give it its long half-life, and tirzepatide is a dual-agonist with its own modifications. A preparation that is nearly right is not therefore nearly as effective — small structural differences can change receptor activity, half-life and immunogenicity in ways that are not proportionate to how small they look on paper.

This is also why identity confirmation matters more here than intuition suggests, and why mass alone is a weak identity check: purity and identity have limits that a certificate rarely spells out.

The unit problem, which is where people get hurt

The most consistent harm reported from the compounded era was not contamination. It was arithmetic.

An authorised pen delivers a dose the device sets. A vial delivers whatever volume you draw, at whatever concentration that particular preparation was made to, measured on whatever syringe you were given. Concentrations differ between preparations. Syringes are commonly graduated in insulin units rather than millilitres. Instructions get given verbally, or in a message, or in a leaflet written for a different concentration. Regulators in several countries issued warnings about dosing errors of this exact shape, including tenfold overdoses, and several of them involved people who had done arithmetic carefully with the wrong starting number.

If you are moving to or from a vial-based preparation, treat the units as the dangerous part. Write down the concentration in milligrams per millilitre. Write down the volume for your dose. Have the pharmacy or prescriber confirm both in writing. Then check it again cold the next day, with the reconstitution tool if it helps, and never work out a dose from a forum post about somebody else’s vial.

Switching, in practice

Plenty of members have moved between categories, usually because of cost, supply or a regulatory change that removed an option overnight. What they report is worth passing on.

Dose equivalence is not guaranteed across a switch. Even where the milligram figure is nominally the same, formulation and delivery differ, and members commonly describe the first fortnight after a switch as feeling like a step change — sometimes more side effects, sometimes noticeably fewer, sometimes an unwelcome return of appetite. Tell your prescriber you are switching rather than presenting it afterwards, because it changes what they should be watching.

Practical things that helped people: don’t switch in the same fortnight as a dose increase; keep the old device or vial until the new arrangement is definitely working, if storage allows; write the concentration on the vial in permanent marker; keep a five-line diary across the transition so that any change has a record behind it; and expect the injection experience itself to differ — needle gauge, volume and sting are all commonly reported as changed.

And if a supply route disappears while you are mid-treatment, shortages and substitutions is the guide for the scramble.

What nobody can tell you

Mira insists this section exists on every guide she reviews, and here it is short.

Nobody can tell you that a given compounded preparation is equivalent to the authorised product, because equivalence is a claim established by studies that have not been done for these preparations. Nobody can tell you it is unsafe either — the honest position is that the assurance is different, not that the outcome is known. Nobody can tell you what your own supply route will look like in a year, because the regulatory ground under all of this has moved repeatedly and is still moving.

What you can do is know which of the three categories you are in, know what that category guarantees and what it leaves open, keep your prescriber informed rather than managing it alone, and treat any change of category as a clinical event rather than an administrative one.